0091 - 755 - 4076518
NRAS Mutation Kit

TRUPCR® BRAF Mutation Kit

The TRUPCR® BRAF Mutation Kit is an in vitro diagnostic test intended for the qualitative detection of BRAF somatic mutations in the genomic DNA extracted from fresh, frozen or formalin fixed paraffin-embedded (FFPE) tissue. The TRUPCR® BRAF mutation kit is based on allele specific amplification and is achieved by ARMS PCR. Taq DNA polymerase is extremely effective at distinguishing between a match and a mismatch at the 3’-end of a PCR primer. The kit is designed to selectively amplify mutant specific sequences in samples that contain a mixture of wild-type and mutated DNA. The most common mutations are found in codon 600. The detection is achieved using fluorescent probes labelled with FAM and HEX. The TRUPCR® BRAF Kit is composed of 7 assays for the detection of the BRAF mutations and a reference control gene of BRAF region without any known polymorphism/mutation.

  • NRAS Mutation Kit

Key Features:

  • Selective Amplification of DNA containing mutation with ARMS Technology.
  • Sensitive to detect up to 1% mutation in BRAF gene.
  • Detects 7 different mutations in a single run.
  • Extraction control included to avoid false-negative results.
  • Rapid, more reliable, comprehensive and cost effective tests.
  • Easy work flow & compatible with various Real Time PCR instruments.

BRAF Detectable mutations:

Tube 1 V600E c.1799T>A COSM476
Tube 2 V600E Complex c.1799_1800TG>AA COSM475
Tube 3 V600D 1799_1800TG>AT COSM477
Tube 4 V600G c.1799T>G COSM6137
Tube 5 V600K c.1798_1799GT>AA COSM473
Tube 6 V600M BRAF c.1798G>A COSM1130
Tube 7 V600R c.1798_1799GT>AG COSM474

The RAS/RAF/MEK/ERK pathway is a critical proliferation pathway in many human cancers. This pathway can be constitutively activated by alterations in specific proteins, including BRAF, which phosphorylates MEK on 2 regulatory serine residues. Over 45 cancer-associated mutations have been identified in BRAF. BRAF mutations have been identified at a high frequency in specific cancers, including approximately 50 to 60% of melanoma, Approximately 90% of all identified BRAF mutations that occur in human cancer are a T1799A transversion mutation in exon 15, which results in a V600E amino acid substitution. This mutation appears to mimic regulatory phosphorylation, locks the BRAF kinase in its active status, and increases BRAF activity approximately 10-fold compared to wild type (2). T1799A alteration (V600E mutation) accounts for 70 to 90% of BRAF mutant melanoma patients. In addition, the T1799A alteration could be associated with a second nucleotide mutation (G1798A) and leads to a V600K mutation in an additional ~6% to 29% of patients with a BRAF mutation

Ordering Information:

3B1287/3B1288 TRUPCR® BRAF Mutation Kit 24/48 Rxn
Scroll to Top